Mepolizumab 100 mg vs placebo
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyHazard ratio 0.78 [0.66, 0.92]2 studies · 981 participantsHigh